Capricor (CAPR) 24-Month HOPE-3 Data Show Deramiocel Slows Upper-Limb Decline

Capricor Therapeutics [[vf-ticker:CAPR]] released 24-month data from the HOPE-3 open-label extension on September 17, 2026, showing Deramiocel meaningfully slowed upper-limb functional decline in Duchenne muscular dystrophy patients versus placebo. The readout arrives ahead of a November 22, 2026 FDA decision on the BLA. For more timely biotech and pharma market coverage, visit the Market News hub.

What happened

Capricor presented the 24-month HOPE-3 extension results at the 2026 World Muscle Society Congress. The data showed Deramiocel reduced the rate of upper-limb function deterioration compared to placebo, supporting the therapy's proposed indication focused on this primary endpoint. The company had previously disclosed the 12-month HOPE-3 data, and the extension demonstrates sustained treatment effect over two years.

The FDA extended Capricor's PDUFA target action date from August 22, 2026 to November 22, 2026, classifying the BLA submission as a major amendment. The agency requested review of the 24-month extension data along with additional analyses supporting the proposed upper-limb function indication. Capricor filed the 8-K disclosing the extension on August 24, 2026.

CAPR shares traded at $11.24 on September 30, 2026, down 1.61% in the session, as the stock continued digesting September volatility following clinical data disclosures. The company carries a market capitalization of approximately $651 million with no approved revenue, consistent with its clinical-stage status.

Why it matters

The 24-month HOPE-3 data provide the longest controlled look at Deramiocel's effect on upper-limb function in DMD. Upper-limb preservation represents a clinically meaningful outcome for Duchenne patients, as respiratory and cardiac decline often follows limb weakness, making hand and arm function critical for independence.

The BLA's focus on upper-limb function as the primary indication represents a targeted regulatory strategy. By narrowing the proposed label to a measurable, function-based endpoint rather than broader disease modification, Capricor may increase the probability of approval. The FDA's classification of the amendment as a major submission signals substantive data review rather than procedural delay.

For investors weighing the binary nature of this catalyst, the two-year dataset strengthens the efficacy narrative compared to shorter-duration reads. The data also positioned favorably against established DMD disease-progression models, giving clinicians and regulators additional context for interpreting results.

What to watch next

The November 22, 2026 PDUFA date represents the primary near-term catalyst. Investors should monitor for any FDA requests for advisory committee meetings or additional information, which could signal approvability questions.

Follow any September World Muscle Society Congress follow-up publications or physician commentary, as real-world clinician reception influences prescribing expectations post-approval.

Track CAPR's cash position and burn rate heading into the decision. Capricor reported Q1 2026 operating expenses of $36.77 million with no revenue, making runway planning critical if approval triggers commercial investment.

Monitor for any updates on Capricor's manufacturing scale-up plans or partnership discussions, as supply chain readiness for a rare disease therapy can influence launch timelines post-approval.